MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial. - Fürstenau M; Robrecht S; Schneider C; Tausch E; Giza A; Ritgen M; Bittenbring J; Hebart H; Schöttker B; Illert AL; Graeven U; Stoltefuß A; et al. (Blood, 2025)